TY - JOUR
T1 - Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease
AU - Favaloro, Emmanuel J
AU - Thom, Jim
AU - Patterson, David
AU - Just, Sarah
AU - Baccala, Maria
AU - Dixon, Tracy
AU - Meiring, Muriel
AU - Koutts, Jerry
AU - Rowell, John
AU - Baker, Ross
PY - 2009/9
Y1 - 2009/9
N2 - We performed a retrospective audit of cross-laboratory testing of desmopressin and factor concentrate therapy to assess the potential utility of supplementary testing using the PFA-100 with functional von Willebrand factor (VWF) activity testing. Data were evaluated for a large number of patients with von Willebrand disease of type 1, type 2A or type 2M, as well as a comparative subset of individuals with haemophilia or carriers of haemophilia. Laboratory testing comprised pre and postdesmopressin, or pre and postconcentrate, evaluation of factor VIII, VWF antigen (VWF:Ag) and VWF ristocetin cofactor activity as traditionally performed, supplemented with collagen-binding (VWF:CB) testing and PFA-100 closure times. In brief, both therapies tended to normalize VWF test parameters and closure times in individuals with type 1 von Willebrand disease, with the level of correction in closure times related to the level of normalization of VWF, particularly the VWF:CB. However, although occasional correction of closure times was observed in patients with type 2A or type 2M von Willebrand disease, these did not in general normalize PFA-100 closure times either with desmopressin or factor concentrate therapy. In these patients, improvement in closure times was more likely in those in whom VWF:CB values normalized or when VWF:CB/VWF:Ag ratios normalized. This study confirms that there is a strong relationship between the presenting levels of plasma VWF and PFA-100 closure times, and that the supplementary combination of PFA-100 and VWF:CB testing might provide added clinical utility to current broadly applied testing strategies limited primarily to VWF:Ag, VWF ristocetin cofactor and factor VIII:coagulant. Future prospective investigations are warranted to validate these relationships and to investigate their therapeutic implications.
AB - We performed a retrospective audit of cross-laboratory testing of desmopressin and factor concentrate therapy to assess the potential utility of supplementary testing using the PFA-100 with functional von Willebrand factor (VWF) activity testing. Data were evaluated for a large number of patients with von Willebrand disease of type 1, type 2A or type 2M, as well as a comparative subset of individuals with haemophilia or carriers of haemophilia. Laboratory testing comprised pre and postdesmopressin, or pre and postconcentrate, evaluation of factor VIII, VWF antigen (VWF:Ag) and VWF ristocetin cofactor activity as traditionally performed, supplemented with collagen-binding (VWF:CB) testing and PFA-100 closure times. In brief, both therapies tended to normalize VWF test parameters and closure times in individuals with type 1 von Willebrand disease, with the level of correction in closure times related to the level of normalization of VWF, particularly the VWF:CB. However, although occasional correction of closure times was observed in patients with type 2A or type 2M von Willebrand disease, these did not in general normalize PFA-100 closure times either with desmopressin or factor concentrate therapy. In these patients, improvement in closure times was more likely in those in whom VWF:CB values normalized or when VWF:CB/VWF:Ag ratios normalized. This study confirms that there is a strong relationship between the presenting levels of plasma VWF and PFA-100 closure times, and that the supplementary combination of PFA-100 and VWF:CB testing might provide added clinical utility to current broadly applied testing strategies limited primarily to VWF:Ag, VWF ristocetin cofactor and factor VIII:coagulant. Future prospective investigations are warranted to validate these relationships and to investigate their therapeutic implications.
KW - Blood Coagulation Factors/therapeutic use
KW - Deamino Arginine Vasopressin/therapeutic use
KW - Drug Monitoring/instrumentation
KW - Factor VIII/analysis
KW - Hemophilia A/blood
KW - Heterozygote
KW - Humans
KW - Platelet Function Tests/instrumentation
KW - Retrospective Studies
KW - Time Factors
KW - von Willebrand Disease, Type 1/blood
KW - von Willebrand Disease, Type 2/blood
KW - von Willebrand Diseases/blood
KW - von Willebrand Factor/analysis
U2 - 10.1097/MBC.0b013e32832da1ad
DO - 10.1097/MBC.0b013e32832da1ad
M3 - Article
C2 - 19584715
SN - 0957-5235
VL - 20
SP - 475
EP - 483
JO - Blood Coagulation and Fibrinolysis: international journal in haemostasis and thrombosis
JF - Blood Coagulation and Fibrinolysis: international journal in haemostasis and thrombosis
IS - 6
ER -